期刊文献+

Ankylosing spondylitis: etiology, pathogenesis, and treatments 被引量:51

Ankylosing spondylitis: etiology, pathogenesis, and treatments
在线阅读 下载PDF
导出
摘要 Ankylosing spondylitis(AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain;additionally, in more advanced cases, it can cause spine fusion. Significant progress in its pathophysiology and treatment has been achieved in the last decade. Immune cells and innate cytokines have been suggested to be crucial in the pathogenesis of AS, especially human leukocyte antigen(HLA)?B27 and the interleukin?23/17 axis.However, the pathogenesis of AS remains unclear. The current study reviewed the etiology and pathogenesis of AS, including genome-wide association studies and cytokine pathways. This study also summarized the current pharmaceutical and surgical treatment with a discussion of future potential therapies. Ankylosing spondylitis(AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain; additionally, in more advanced cases, it can cause spine fusion. Significant progress in its pathophysiology and treatment has been achieved in the last decade. Immune cells and innate cytokines have been suggested to be crucial in the pathogenesis of AS, especially human leukocyte antigen(HLA)?B27 and the interleukin?23/17 axis.However, the pathogenesis of AS remains unclear. The current study reviewed the etiology and pathogenesis of AS, including genome-wide association studies and cytokine pathways. This study also summarized the current pharmaceutical and surgical treatment with a discussion of future potential therapies.
出处 《Bone Research》 SCIE CAS CSCD 2019年第3期243-258,共16页 骨研究(英文版)
基金 supported by the Beijing Natural Science Foundation youth project (7184325) the China Postdoctoral Foundation NO.62 general program
  • 相关文献

参考文献4

二级参考文献86

  • 1惠萍,杜洛山,梁丽.幼年强直性脊柱炎临床X线分析[J].中华放射学杂志,1994,28(6):382-384. 被引量:8
  • 2Jacobi AM,Odendahl M,Reiter K,Brans A,Burmester GR,Radbrach A,et al.Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.Arthritis Rheum 2003;48:1332-1342.
  • 3Odendahl M,Jacobi A,Hansen A,Feist E,Hiepe E Burmester GR,et al.Disturbed peripheral B-cell homeostasis in systemic lupus erythematosus.J Immunol 2000;165:5970-5979.
  • 4Lindenau S,Scholze S,Odendahl M,Dorner T,Radbruch A,Burmester GR,et al.Aberrant activation of B-cells in patients with rheumatoid arthritis.Ann N Y Acad Sci 2003;987:246-248.
  • 5Toussirot E,Lafforgue E Boucrant J,Despieds E Schiano A,Bernard D,et ai.Serum levels of interleukin 1-beta,tumor necrosis factor-alpha soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies.Rheumatol Int 1994;13:175-180.
  • 6Gorman JD,Sack KE,Davis JC Jr.Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.N Engl J Meal 2002;346:1349-1356.
  • 7McLeod C,Bagust A,Boland A,Dagenais P,Dickson R,Dundar Y,et al.Adalimumab,etanercept and infliximab for the treatment of ankylosing spondylitis:a systematic review and economic evaluation.Health Technol Assess 2007;11:1-158,iii-iv.
  • 8Davis JC Jr,van tier Heijde DM,Braun J,Dougados M,Clegg DO,Kivitz AJ,et al.Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.Ann Rheum Dis 2008;67:346-352.
  • 9Calin A,Dijkmans BA,Emery P,Hakala M,Kalden J,Leirisalo-Repo M,et al.Outcomes of a multicenter randomized clinical trial of etanercept to treat ankylosing spondylitis.Ann Rheum Dis 2004;63:1594-1600.
  • 10Van der Linden S J,Valkenburg HA,Cats A.Evaluation of diagnostic criteria for ankylosing spondylitis:a proposal for modification of the New York criteria.Arthritis Rheum 1984;27:361-368.

共引文献45

同被引文献475

引证文献51

二级引证文献132

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部